About Us

BRT Biotechnologies is aiming to drug the undruggable. Our proprietary platform allows for ultra-high-throughput synthesis of large and diverse macrocycle libraries that can be directly screened for activity. Our synthetic approach uses no tags and no barcodes and our libraries are ready for your phenotypic or target-based drug discovery screen.

Founders

The BRT Bio team, which has successfully invented and commercialized leading drug discovery technologies backed by leading investors in the past, has a proprietary platform, BRiTeCycle, that provides large libraries of macrocycles for drug discovery programs, as well as follow-up support that can accelerate drug discovery.

Jane Liu, CEO

Expertise in biochemical screens and selections. Successful in securing funding and team management.

Greg Copeland, CSO

Expertise in solid-phase chemistry, library synthesis, and microfluidics.

BRT Biotechnologies

Your partner of choice for macrocycle drug discovery

About Us

Founders

Jane Liu, CEO

Greg Copeland, CSO

Partners

Have any questions?